<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>isfcppharmaspire</PublisherName>
      <JournalTitle>Pharmaspire</JournalTitle>
      <PISSN>C</PISSN>
      <EISSN>o</EISSN>
      <Volume-Issue/>
      <PartNumber/>
      <IssueTopic>Multidisciplinary</IssueTopic>
      <IssueLanguage>English</IssueLanguage>
      <Season/>
      <SpecialIssue>N</SpecialIssue>
      <SupplementaryIssue>N</SupplementaryIssue>
      <IssueOA>Y</IssueOA>
      <PubDate>
        <Year>-0001</Year>
        <Month>11</Month>
        <Day>30</Day>
      </PubDate>
      <ArticleType>Pharmaceutics</ArticleType>
      <ArticleTitle>Challenges in utilizing Diethylene Glycol and Ethylene Glycol as excipient: A Thorough Overview</ArticleTitle>
      <SubTitle/>
      <ArticleLanguage>English</ArticleLanguage>
      <ArticleOA>Y</ArticleOA>
      <FirstPage>0</FirstPage>
      <LastPage>0</LastPage>
      <AuthorList>
        <Author>
          <FirstName>Ashmeen</FirstName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>N</CorrespondingAuthor>
          <ORCID/>
        </Author>
      </AuthorList>
      <DOI/>
      <Abstract>Diethylene glycol (DEG) and ethylene glycol (EG) are widely used excipients in pharmaceutical formulations, such as oral and topical preparations, due to their unique physical and chemical properties. However, the use of these glycols as excipients has been associated with numerous challenges, including their potential toxicity and regulatory concerns. The challenges associated with the use of DEG and EG as excipients, including their physicochemical properties, toxicity concerns, and regulatory requirements. Discusses the toxicological properties of DEG and EG, including their mechanism of toxicity. It also highlights the regulatory guidelines governing the use of these excipients in pharmaceuticals and the measures that can be taken to mitigate the risks associated with their use. Overall, aims to provide a comprehensive understanding of the challenges in utilizing DEG and EG as excipients and emphasizes the need for appropriate risk to patient.</Abstract>
      <AbstractLanguage>English</AbstractLanguage>
      <Keywords>Diethylene Glycol,Ethylene glycol,Acute renal failure,WHO,CDSCO</Keywords>
      <URLs>
        <Abstract>https://isfcppharmaspire.com/ubijournal-v1copy/journals/abstract.php?article_id=14694&amp;title=Challenges in utilizing Diethylene Glycol and Ethylene Glycol as excipient: A Thorough Overview</Abstract>
      </URLs>
      <References>
        <ReferencesarticleTitle>References</ReferencesarticleTitle>
        <ReferencesfirstPage>16</ReferencesfirstPage>
        <ReferenceslastPage>19</ReferenceslastPage>
        <References/>
      </References>
    </Journal>
  </Article>
</ArticleSet>